Skip to main content
. 2019 Nov 21;7:316. doi: 10.1186/s40425-019-0793-8

Table 1.

Characteristics in cohorts A and B according to bone involvement

Characteristic Cohort A Cohort B
Non-squamous BoM+ (N/%) Non-squamous BoM- (N/%) p Squamous BoM+ (N/%) Squamous BoM- (N/%) p
Total patients 626 (39) 962 (61) 120 (32) 251 (68)
Median age (year/range) 65 (29–89) 67 (27–87) 0.001 67 (31–83) 68 (31–91) 0.06
Patients ≥75 years 67 (11) 165 (17) < 0.0001 18 (15) 52 (21) 0.19
Gender
 • Male 401 (64) 628 (65) 96 (80) 202 (81) 0.91
 • Female 225 (36) 334 (35) 0.62 24 (20) 49 (19)
ECOG PS
 • 0 213 (34) 435 (45) < 0.0001 36 (30) 98 (39) 0.25
 • 1 354 (56) 461 (48) 77 (64) 138 (55)
 • 2 57 (9) 51 (5) 7 (6) 15 (6)
 • Unk 2 (1) 15 (2)
Metastatic site
 • liver 178 (28) 149 (16) < 0.00001 25 (21) 38 (15) 0.14
 • brain 191 (30) 218 (23) 0.001 16 (13) 21 (8) 0.17
Previous therapies
 • 1 256 (41) 359 (37) 0.07 54 (44) 108 (43) 0.67
 • 2 176 (28) 281 (29) 37 (31) 83 (33)
 • 3 118 (19) 162 (17) 20 (17) 48 (19)
 • > 3 74 (12) 154 (16) 9 (8) 12 (5)
Smoking status
 • Never smoker 134 (21) 171 (18) 0.06 13 (11) 18 (7) 0.14
 • Former smoker 308 (49) 457 (48) 69 (57) 156 (62)
 • Active smoker 134 (21) 226 (23) 23 (19) 60 (24)
 • Unk 50 (8) 108 (11) 15 (13) 17 (7)
EGFR status
 • Mutated 47 (8) 55 (6) 0.10
 • Wild-type 514 (82) 779 (81)
 • Unk 65 (10) 128 (13)
KRAS status
 • Mutated 91 (15) 115 (12) 0.23
 • Wild-type 132 (21) 192 (20)
 • Unk 403 (64) 655 (68)
BRAF status
 • Mutated 5 (1) 6 (1) 0.54
 • Wild-type 85 (14) 114 (12)
 • Unk 536 (85) 842 (87)
ALK status
 • Mutated 5 (1) 11 (1) 0.51
 • Wild-type 407 (65) 645 (67)
 • Unk 214 (34) 306 (32)
ROS1 status
 • Mutated 3 (1) 1 (1) 0.29
 • Wild-type 142 (23) 207 (21)
 • Unk 481 (76) 754 (78)

Unk Unknown